FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

VC: Cerenis garners $53.5M in second round



Cerenis garners $53.5M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Cerenis Therapeutics
Ann Arbor, MI and Toulouse, France

$53.5M
Second

TVM Capital

Cerenis says much of the money will be used to back the development of its lead compound, Cerenis HDL, a synthetic form of HDL that mimics natural HDL.

EyeGate Pharma
Waltham, MA

$10M
Second

Innoven Partenaires and Ventech

EyeGate is researching new drug/device therapies for macular degeneration and other eye diseases.

Yaupon Therapeutics
Radnor, PA

$4M
Second

Osage Ventures

The financing will support the continued development of Yaupon's multiple clinical programs targeting diverse medical needs in the treatment of lymphoma, addiction and neuropathic pain.

More stories about Venture Capital   macular degeneration   neuropathic pain  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 24 + 48?
To combat spam, please solve the math question above.